Bioray Pharmaceutical Co. Ltd. has prepared and tested new antibody-drug conjugates consisting of antibodies covalently linked to payloads. They are reported to be potentially useful for the treatment of cancer, infections, inflammatory and immunological disorders.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged new antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to a cytotoxic drug potentially useful for the treatment of colorectal cancer.
HCW Biologics Inc. has requested a type B (pre-IND) meeting with the FDA to discuss the development and regulatory strategy for its investigational tetravalent T-cell engager (TCE), HCW-11-018b, for solid tumors.
Shanghai Escugen Biotechnology Co. Ltd. has disclosed new antibody-drug conjugates comprising chimeric monoclonal antibodies targeting CD174 (Lewis y) covalently linked to a cytotoxic drug. They are potentially useful for the treatment of cancer.
Tikva Allocell Pte. Ltd. has closed an $8 million series A financing to support its development of engineered, allogeneic cell therapies for adult and pediatric patients with solid tumors.
Verismo Therapeutics Inc. has reported a new preclinical KIR-CAR program targeting the Claudin 6 (CLDN6) antigen to treat CLDN6-expressing solid tumors. The program is built around a CLDN6-directed binder discovered at the University of Pennsylvania Perelman School of Medicine through a Verismo-sponsored research agreement.
Mediboston Biologics Co. Ltd. has disclosed new antibody-drug conjugates comprising an antibody or antigen-binding fragment covalently linked to a camptothecin derivative potentially useful for the treatment of cancer.
Breezebio Inc. (formerly Genedit Inc.) has entered into a joint research agreement with Ligachem Biosciences Inc. to develop innovative cancer vaccine therapies.
Akari Therapeutics plc has established a strategic research collaboration with Whitehawk Therapeutics Inc. to conduct preclinical studies evaluating Akari’s proprietary PH1 spliceosome-modulating payload technology in combination with Whitehawk’s topoisomerase I inhibitor antibody-drug conjugate platform.
Investigators at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have demonstrated that in the liver, some endothelial cells (ECs) acted as antigen-presenting cells of sorts. These lipoprotein lipase (LPL)-expressing cells cross-presented tumor antigens on their surface, alerting T cells to the presence of metastases.
RSS
